# Guosheng Capital

> Guosheng Capital is a VC fund in Chengdu backing Biotechnology, Medical and Health Care. See 20 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Chengdu, China
- Total investments: 20
- Last investment: Jun 2026
- Lead investor: 25%
- Last updated: Aug 2026

Guosheng Capital is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 11 | 55% |
| Medical | 6 | 30% |
| Health Care | 6 | 30% |
| Pharmaceutical | 4 | 20% |
| Biopharma | 3 | 15% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 9 | 45% |
| Seed | 2 | 10% |
| Series A | 2 | 10% |
| Series C | 2 | 10% |
| Angel | 1 | 5% |

8 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Antekin Biotech | Antekin Biotech is a leading vaccine company with integrated capabilities spanning the entire vaccine value chain, from research and development to manufacturing and commercialization. The company is dedicated to advancing innovative vaccine technologies, enhancing disease prevention, and delivering high-quality vaccine solutions to improve publichealth and address global healthcare challenges. | $143.2M | Corporate Round | Jun 15, 2026 |  |
| Gestala | Gestala is China’s first pioneer in ultrasound-based Brain-Computer Interface (BCI). We are dedicated to engineering a platform with full-brain read-write capabilities, offering transformative therapeutic modalities for neurological disorders. Beyond clinical impact, we aim to decode the neural code and pave the way for a symbiotic future wherebrain science and artificial intelligence converge. | $21.8M | Angel | Mar 12, 2026 |  |
| Lande Energy | Lande Energy is a joint-stock company primarily engaged in the research, application, promotion, production, and sales of new energy technologies, environmentally friendly green synthesis technologies, and biomedicine. |  | Series B | Feb 02, 2026 |  |
| Zenitar | Baoling Bio is an innovative drug research and development and industrialization service provider. The company's research and development pipeline covers the research and development of innovative drugs such as tumors (solid tumors and hematomas), autoimmune diseases, and cytokine storms caused by new coronavirus pneumonia. | $86M | Series C | Jan 12, 2026 |  |
| MAXVAX | MAXVAX aims to provide novel vaccine development and commercialization. |  | Series D | Dec 25, 2025 |  |
| Novel medical | Novel medical is a company focusing on the research and development of medical equipment and devices |  | Series B | Nov 30, 2025 |  |
| Enze Kangtai | Echo Biotech is a biotech firm mainly engaged in the R&D and production of exosome molecular diagnostic products and exosome research. | $14M | Series B | Nov 06, 2025 |  |
| Heerkang | Heerkang is a medical technology company that provides medical device research and sales, and health consultation services. |  | Series A | Nov 04, 2025 |  |
| Affinity | Affinity Biomedical Technology is a clinical biopharmaceutical company focusing on the development of global innovative anticancer drugs. | $42.1M | Series B | Sep 09, 2025 |  |
| Yanshengchao | Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China | $12.2M | Seed | Aug 04, 2025 |  |

10 of 20 investments shown.

## Co-investors
- [Chengdu Science and Technology Venture Capital](https://shizune.co/investors/profile/chengdu-science-and-technology-venture-capital-group) — VC Fund, 2 deals together
- [Dalton Venture](https://shizune.co/investors/profile/dalton-venture) — VC Fund, 2 deals together
- Hongfu Assets — VC Fund, 2 deals together
- [Legend Capital](https://shizune.co/investors/profile/legend-capital) — VC Fund, 2 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- Anxin Guosheng Microchip Fund — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Guosheng Capital invest in?

Guosheng Capital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series B and Seed stage. Most of the 20 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Guosheng Capital last invest?

The most recent investment recorded for Guosheng Capital closed in Jun 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co